[go: up one dir, main page]

CL2008000786A1 - Composicion farmaceutica proliposomal que comprende un concentrado de: un lipido formador de membranas con uno o mas fosfolipidos saturado o no saturado, un agente estabilizador de membrana seleccionado de un compuesto esterol y un vehiculo como un s - Google Patents

Composicion farmaceutica proliposomal que comprende un concentrado de: un lipido formador de membranas con uno o mas fosfolipidos saturado o no saturado, un agente estabilizador de membrana seleccionado de un compuesto esterol y un vehiculo como un s

Info

Publication number
CL2008000786A1
CL2008000786A1 CL200800786A CL2008000786A CL2008000786A1 CL 2008000786 A1 CL2008000786 A1 CL 2008000786A1 CL 200800786 A CL200800786 A CL 200800786A CL 2008000786 A CL2008000786 A CL 2008000786A CL 2008000786 A1 CL2008000786 A1 CL 2008000786A1
Authority
CL
Chile
Prior art keywords
saturated
membrane
concentrate
vehicle
pharmaceutical composition
Prior art date
Application number
CL200800786A
Other languages
English (en)
Inventor
Dhiraj Kumar Mukesh Mu Khattar
Original Assignee
Dabur Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dabur Pharma Ltd filed Critical Dabur Pharma Ltd
Publication of CL2008000786A1 publication Critical patent/CL2008000786A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL200800786A 2007-03-19 2008-03-18 Composicion farmaceutica proliposomal que comprende un concentrado de: un lipido formador de membranas con uno o mas fosfolipidos saturado o no saturado, un agente estabilizador de membrana seleccionado de un compuesto esterol y un vehiculo como un s CL2008000786A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN590DE2007 2007-03-19

Publications (1)

Publication Number Publication Date
CL2008000786A1 true CL2008000786A1 (es) 2008-09-26

Family

ID=39620132

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800786A CL2008000786A1 (es) 2007-03-19 2008-03-18 Composicion farmaceutica proliposomal que comprende un concentrado de: un lipido formador de membranas con uno o mas fosfolipidos saturado o no saturado, un agente estabilizador de membrana seleccionado de un compuesto esterol y un vehiculo como un s

Country Status (8)

Country Link
US (1) US20090017105A1 (es)
EP (1) EP2146692A1 (es)
AR (1) AR065805A1 (es)
AU (1) AU2008227852B2 (es)
CA (1) CA2681302C (es)
CL (1) CL2008000786A1 (es)
TW (1) TWI355946B (es)
WO (1) WO2008114274A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US20140335166A1 (en) * 2013-05-08 2014-11-13 Michael W. Fountain Methods of Making and Using Nano Scale Particles
KR101066197B1 (ko) * 2009-04-06 2011-09-20 한국생명공학연구원 코엔자임 ｑ10 나노입자, 그 제조방법 및 상기 나노입자를 포함하는 조성물
PL214538B1 (pl) * 2009-05-28 2013-08-30 P P F Hasco Lek Spolka Akcyjna Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US9402812B2 (en) * 2009-09-23 2016-08-02 Indu JAVERI Methods for the preparation of liposomes
CA2782911C (en) 2009-12-03 2016-08-23 Jiangsu Hengrui Medicine Co., Ltd. Liposome of irinotecan or its hydrochloride and preparation method thereof
WO2011139899A2 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
SG10201702240TA (en) * 2012-05-09 2017-05-30 Univ Western Health Sciences Proliposomal testosterone formulations
JP2015516411A (ja) * 2012-05-10 2015-06-11 ペインレフォーム リミテッド 疎水性有効成分のデポー製剤及びその調製方法
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CN103768018A (zh) * 2012-10-17 2014-05-07 南京绿叶思科药业有限公司 一种卡巴他赛脂质体注射剂及其制备方法
US20150132369A1 (en) * 2013-11-09 2015-05-14 Exir Nano Sina Company Nanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof
EP3265059A4 (en) * 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
EP3265063A4 (en) * 2015-03-03 2018-11-07 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
CN108348480A (zh) 2015-08-20 2018-07-31 益普生生物制药有限公司 使用脂质体伊立替康和parp抑制剂用于癌症治疗的组合疗法
CN105055322A (zh) * 2015-09-02 2015-11-18 厦门市壳聚糖生物科技有限公司 甲氨喋呤磷脂复合物、其纳米粒子及其靶向缓释制剂三者的制备方法
EP3360577A4 (en) * 2015-10-07 2019-06-12 Ensuiko Sugar Refining Co., Ltd. LIPOSOM WITH TAXAN CONNECTION
EP3399965A4 (en) * 2016-01-08 2019-08-21 Western University Of Health Sciences PROLIPOSOMAL TESTOSTERONE ANDECANOATE FORMULATIONS
CN107362142B (zh) * 2016-05-13 2023-04-25 山东新时代药业有限公司 一种氟维司群脂质体注射液及其制备方法
JP2019533006A (ja) 2016-09-09 2019-11-14 アイリシス・インコーポレイテッド リポソーム抗がん組成物
SG11201903326RA (en) 2016-10-28 2019-05-30 Servier Lab Liposomal formulation for use in the treatment of cancer
EP3538074B1 (en) * 2016-11-11 2023-07-26 Western University Of Health Sciences Methods of treating upper tract urothelial carcinomas
CN108926533B (zh) * 2017-05-24 2022-03-25 江苏天士力帝益药业有限公司 一种替西罗莫司脂质体及其制备方法
WO2019082139A1 (en) * 2017-10-27 2019-05-02 Shilpa Medicare Limited LIPOSOMAL FINGOLIMOD HYDROCHLORIDE INJECTION
AU2018374593B2 (en) * 2017-11-30 2021-09-09 Shilpa Medicare Limited Composition of docetaxel liposomal injection with high drug loading
CN110368500B (zh) * 2019-07-12 2020-06-30 浙江大学 一种两亲性共聚物药物前体、制备方法以及包载钙泊三醇的纳米颗粒
CN112076158B (zh) * 2020-08-28 2023-12-08 西南民族大学 一种治疗慢性肾炎的脂质体-纳米粒复合体
CN113181113A (zh) * 2021-04-28 2021-07-30 四川科伦药业股份有限公司 一种甲硝唑氯化钠注射液的制备方法
CN119857064B (zh) * 2025-03-25 2025-06-24 广州市芊彩化妆品有限公司 一种深层滋养的护发素及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744989A (en) * 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
JPH0753661B2 (ja) * 1984-03-08 1995-06-07 フアレス フアーマスーチカル リサーチ エヌブイ プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5262168A (en) * 1987-05-22 1993-11-16 The Liposome Company, Inc. Prostaglandin-lipid formulations
WO1990011780A1 (en) * 1989-03-31 1990-10-18 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5498420A (en) * 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
ES2154680T3 (es) * 1993-07-08 2001-04-16 Liposome Co Inc Metodo para controlar el tamaño de los liposomas.
SA95160463B1 (ar) * 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
US5753262A (en) * 1995-06-07 1998-05-19 Aronex Pharmaceuticals, Inc. Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof
GB2331924A (en) * 1997-12-08 1999-06-09 Phares Pharm Res Nv Lipid compositions and their use
ATE312599T1 (de) * 1999-10-01 2005-12-15 Lipoxen Technologies Ltd Impfstoffe zur oralen verwendung die liposomen sowie eine nukleinsäure enthalten
US6761901B1 (en) * 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
DK2286795T3 (en) * 2002-06-26 2017-02-06 Syncore Biotechnology Co Ltd PROCEDURE FOR PREPARING A Cationic LIPOSOMAL PREPARATION INCLUDING A LIPOPHIL COMPOUND
WO2004047802A2 (en) * 2002-11-26 2004-06-10 Gilead Sciences, Inc. Liposomal formulations
KR20050105455A (ko) * 2003-02-11 2005-11-04 네오팜 인코포레이티드 리포좀 제제의 제조 방법
EP1666486A4 (en) * 2003-09-03 2006-12-06 Kyowa Hakko Kogyo Kk COMPOUND WITH A GLYCERIN DERIVATIVE COMPOUND
KR101376895B1 (ko) * 2004-05-03 2014-03-25 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
EP2007355A2 (en) * 2005-12-08 2008-12-31 Wyeth a Corporation of the State of Delaware Liposomal compositions
US9814672B2 (en) * 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi

Also Published As

Publication number Publication date
US20090017105A1 (en) 2009-01-15
AU2008227852B2 (en) 2011-02-24
CA2681302A1 (en) 2008-09-25
TWI355946B (en) 2012-01-11
WO2008114274A1 (en) 2008-09-25
CA2681302C (en) 2013-07-23
EP2146692A1 (en) 2010-01-27
AU2008227852A1 (en) 2008-09-25
AR065805A1 (es) 2009-07-01
TW200904483A (en) 2009-02-01

Similar Documents

Publication Publication Date Title
CL2008000786A1 (es) Composicion farmaceutica proliposomal que comprende un concentrado de: un lipido formador de membranas con uno o mas fosfolipidos saturado o no saturado, un agente estabilizador de membrana seleccionado de un compuesto esterol y un vehiculo como un s
CR20110080A (es) 4-fenil-1h-pirazoles insecticidas
UY32327A (es) Antagonistas de receptores de ácido lisofosfatídico
CL2008000531A1 (es) Compuestos derivados de heterociclos, inhibidores de la aspartilproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades cardiovasculares, cognitivas y neurodegenerativas tales como la enfermeda
PT2821386T (pt) Composição cosmética, dermatológica ou farmacêutica que compreende pelo menos um derivado de vanilina como conservante
CL2008000562A1 (es) Uso de compuestos derivados de diaminopirimidina como fungicidas; agente para combatir microorganismos no deseados que contiene a dichos compuestos; procedimiento para combatir microorganismos no deseados; procedimiento de preparacion de dichos agent
CL2007001997A1 (es) Compuestos derivados de tiofeno, agentes inmunomoduladores; composicion farmaceutica que los comprende; y su uso para tratar o prevenir enfermedades o trastornos asociados con un sistema inmunologico activado, tales como rechazo de organos transplant
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
CL2007003804A1 (es) Compuestos derivados de indazol; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar condiciones inflamatorias, tales como asma, epoc.
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
CO6680708A2 (es) Compuesto modulares de estrógenos y composiciones que comprenden los mismos
CL2015001486A1 (es) Composición que comprende agentes de control biológico.
BR112014029222A2 (pt) composições que compreendem um agente de controle biológico e um inseticida
BR112014029122A2 (pt) composições que compreendem um agente de controle biológico e um inseticida
BRPI0923589A2 (pt) uso de uma composição espumável essencialmente livre de ingredientes farmaceuticamente ativos para o tratamento da pele humana.
UY32659A (es) Pirazinilpirazoles
BR112014029118A2 (pt) composições que compreendem um agente de controle biológico e um inseticida
BRPI1013259B8 (pt) moduladores lxr
BRPI0914410A2 (pt) composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares.
MX362167B (es) Formulaciones de fungicida para pvc plastificado.
CR20110660A (es) Mezclas fungicidas
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
BR112013000706A2 (pt) reforço tendo uma estrutura de três camadas e emplastro aquoso usando o reforço
CL2008000217A1 (es) Combinaciones de compuestos activos que comprenden la formononetina y al menos un compuesto activo; uso de dicha combinacion para controlar hongos fitopatogenos no deseados; y procedimiento para controlar hongos fitopatogenos no deseados.